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Abstract
Background: DanQi pill (DQP) is prescribed widely in China and has definite cardioprotective effect on coronary
heart disease. Our previous studies proved that DQP could effectively regulate plasma levels of high density
lipoprotein (HDL) and low density lipoprotein (LDL). However, the regulatory mechanisms of DQP and its major
components Salvianolic acids and Panax notoginseng saponins (DS) on lipid metabolism disorders haven’t been
comprehensively studied so far.
Methods: Rat model of coronary heart disease was induced by left anterior descending (LAD) artery ligation operations.
Rats were divided into sham, model, DQP treated, DS treated and positive drug (clofibrate) treated groups. At 28 days
after surgery, cardiac functions were assessed by echocardiography. Expressions of transcription factors and key molecules
in energy metabolism pathway were measured by reverse transcriptase polymerase chain reaction or western blotting.
Results: In ischemic heart model, cardiac functions were severely injured but improved by treatments of DQP and DS.
Expression of LPL was down-regulated in model group. Both DQP and DS could up-regulate the mRNA expression of
LPL. Membrane proteins involved in lipid transport and uptake, such as FABP4 and CPT-1A, were down-regulated in
ischemic heart tissues. Treatment with DQP and DS regulated lipid metabolisms by up-regulating expressions of FABP4
and CPT-1A. DQP and DS also suppressed expression of cytochrome P450. Furthermore, transcriptional factors,
such as PPARα, PPARγ, RXRA and PGC-1α, were down-regulated in ischemic model group. DQP and DS could
up-regulate expressions of these factors. However, DS showed a better efficacy than DQP on PGC-1α, a
coactivator of PPARs. Key molecules in signaling pathways such as AKT1/2, ERK and PI3K were also regulated
by DQP and DS simultaneously.
Conclusions: Salvianolic acids and Panax notoginseng are the major effective components of DanQi pill in
improving lipid metabolism in ischemic heart model. The effects may be mediated by regulating transcriptional factors
such as PPARs, RXRA and PGC-1α.
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Background
Coronary heart disease (CHD) induced by atheroscler-
osis remains one of the major threats to people’s health
and one of the main causes of death, despite our better
understanding of the pathophysiology of CHD and
advances in treatment methods [1]. In developing coun-
tries, the incidence of CHD has been rising in recent
years [2]. It’s of paramount importance to develop novel
therapies for CHD so as to reduce the economic and
health burden caused by it.
Managements of CHD include life style changes,
medication and surgical procedures [3, 4]. Antihyperten-
sive drugs such as ACEIs and lipid lowering drugs are
the most commonly prescribed medications. Traditional
Chinese medicine (TCM) has also been used to treat
CHD for a long period of time. DanQi Pill (DQP),
composed of Radix Salvia Miltiorrhiza (Danshen) and
Panax notoginseng (Sanqi), is among the most com-
monly prescribed TCM [5] Salvianolic acids are the
water soluble compounds extracted from Radix Salvia
Miltiorrhizae [6, 7], and Panax notoginseng saponins
are the major active components of Panax notogein-
seng [8, 9]. Exploration of the pharmacological mech-
anisms of DQP will provide insight into the treatment
of CHD and development of new drugs.
Our previous studies proved that DQP could effect-
ively regulate plasma levels of high density lipoprotein
(HDL) and low density lipoprotein (LDL) in rat models
of CHD [9]. DQP could also modulate cardiac energy
metabolism that has been disturbed under ischemic con-
ditions [10]. In ischemic heart disease, overall mitochon-
drial oxidative catabolism decreases while reliance on
anaerobic glycolysis pathways is increased [11, 12]. Fatty
acids oxidation was effectively improved by DQP, as was
shown by up-regulated fatty acids transportation, uptake
and metabolism. DQP exerts cardioprotective effect by
improving energy supply of myocytes. However, the up-
stream transcriptional regulatory effects of DQP haven’t
been studied yet. Furthermore, the effects of compound
formula (DQP) and major components (Salvianolic acids
and Panax notoginseng saponins, DS) haven’t been eval-
uated yet.
The peroxisome proliferator-activated receptor family
(PPARα, β/δ and γ) of nuclear receptor transcription
factors is an important regulator of cardiac metabolism
[12]. The PPARs control myocardial metabolism by
transcriptionally regulating genes encoding enzymes
involved in fatty acid and glucose utilization [13, 14].
Peroxisome proliferator-activated receptor gamma
coactivator-1α (PGC-1α) is transcriptional coactivator
of the PPARs and is a key player in the control of
myocardial metabolism. Activation of PGC-1α drives
a strong induction of PPARs target genes encoding
fatty acid oxidation enzymes [15]. In this study, we
investigated the effects of DQP and the extracts of
DQP (DS, Panax notoginseng saponins and Salvianolic
acids) on PPARs and PGC-1α. The target genes of
these transcriptional regulators involved in energy
metabolism and down-stream signaling pathways were
also detected. Rat model of ischemic coronary heart
disease was applied in this work. This study will pro-
vide further insight into the mechanisms of traditional
Chinese medicine in the management of CHD.
Methods
Animal groupings and induction of myocardial infarction
One hundred Sprague-Dawley (SD) male rats, with
weight of 220 ± 10 g, were randomly divided into five
groups: sham-operated, model, positive control drug
(clofibrate) treated, solutions of DS treated and DQP
treated groups. All the rats were purchased from
Beijing Vital River Laboratory Animal Technology Co.
Ltd, with the license number of SCXK2010 ~ 2011.
The animal experiments were approved by the
Animal Care Committee of Beijing University of
Chinese Medicine. The rats were fed with regular diet
for one week before surgery. Rats in the control
group received sham operation while rats in the other
groups underwent left anterior descending (LAD) ar-
tery ligation surgeries which induced models of ische-
mic heart disease. The operational procedures have
been described in our previous studies [10, 16].
Briefly, left thoracotomies were performed after rats
were anaesthetized by 1% pentobarbital sodium at the
dosage of 50 mg/kg via intraperitoneal injection. LAD
coronary arteries were then ligated with a 5–0 poly-
propylene suture. The thorax was closed after ligation.
Rats in the sham group received the same procedures
except that the coronary arteries were not ligated.
From the second day after surgery, Rats were ran-
domly divided into five groups: sham group fed with
normal diet, model group, clofibrate group (positive
control), DQP group and DS group fed with high fat
diet for 28 days. Rats in the DQP group were treated with
DQP aqueous solution (Tongren tang, Beijing, China, Series:
6128006) at the dosage of 1.5 mg/kg per day via oral gavage
for 28 consecutive days [9]. In DS group, rats received solu-
tions of salvianolic acid (SA) and Panax Notoginseng
Saponins (PNS) at the dosage of 7.5 μg/kg and 82.5 μg/kg
respectively. The dosage of SA and PNS were given accord-
ing to their percentage contained in DQP. Rats in the posi-
tive control group received clofibrate aqueous solution at
the dosage of 0.3 g/kg as reported previously. Animals in
the sham and model groups were given a gavage of normal
saline water for 28 days. The mortality rate of surgery was
22%. After surgery, 19(95%), 15(75%), 14(70%), 16(80%) and
14(70%) rats survived in sham, model, positive control drug
treated, DS treated and DQP treated groups, respectively.
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Measurement of cardiac functions
Echocardiography was applied to assess the cardiac func-
tions at 28d after surgery using a Vevo 2100 (VisualSonics
Inc, Toronto, Ontario, Canada). A PST 65A sector scan-
ner (8-MHz probe) was employed, which generates two-
dimensional images at a frame rate of 300 to 500 frames/s.
The parameters of heart functions include: left ventricular
end-systolic diameter (LVESd), left ventricular end-
diastolic diameter (LVEDd), left ventricular end-diastolic
volume (LVEDv), left ventricular end-systolic volume
(LEVSv), ejection fraction (EF) and fractional shortening
(FS). EF was calculated as follows: EF % = [(LVEDv ‐
LVESv)/LVEDv] × 100%. FS was calculated using the equa-
tion: [(LVEDd ‐ LVESd)/LVEDd] × 100%.
Evaluation of mRNA expressions of key molecules
involved in lipid metabolism pathway
The mRNA expressions of Lipoprotein Lipase (LPL),
cluster of differentiation 36 (CD36) and ATP-binding
cassette transporter (ABCA1) were determined by re-
verse transcriptase polymerase chain reaction (RT-PCR).
Total RNA was extracted using TRIzol Reagent (Gibco-
BRL, Paisley, UK). The concentration of RNA was mea-
sured using Nano Drop 2000 (Thermo Scientific, USA),
and the RNA was then transcribed to cDNA using the
RevertAidTM First Stand cDNA Synthesis kit (Fermentas,
LT). The reaction volume was 20 μl, containing 2 μl
cDNA, 0.5 μl forward and 0.5 μl reverse primers, 10 μl
Rox and 7 μl DEPC. For cDNAs analysis of LPL, ABCA1,
CD36 and GAPDH, PCR conditions were set as follows:
15 s at 95 °C for denaturation, and 1 min at 55 °C for an-
nealing and extension. 40 cycles were run for each gene.
The sequences of the primers were shown at Table 1.
Quantities of each gene were normalized to quantity of
GAPDH mRNA.
Measurement of key proteins in energy metabolism
pathways by western blot (WB)
Left ventricle homogenates were prepared for the ana-
lysis of protein levels. Briefly, the cardiac tissue was ho-
mogenized in RIPA buffer (50 mM Tris-HCl Ph7.4,
150 mM NaCl, 1% NP-40, 0.1%SDS) and total protein
was extracted from this homogenate. The protein con-
centration in each sample extract was measured by a
protein assay kit (Beijing PuLilai Gene Technology Co.,
Ltd, Beijing, China, lot number: P1511). Equal amounts of
protein extracts (20 μg) were separated by 12.5% sodium
dodecyl sulphate(SDS)-polyacrylamide gel electrophoresis
(Bio-Rad, CA, U.S.A.) and transferred to nitrocellulose
membranes electrophoretically (semidry transfer). Mem-
branes were blocked with 5% non-fat dry milk in Tris-
buffered saline (20 mM Tris, pH 7.6, 137 mM NaCl) with
0.1% Tween 20, washed, and then incubated with primary
antibody. Primary antibodies employed included: goat
polyclonal anti-glyceraldehyde-3-phosphate dehydrogen-
ase(GAPDH) and anti- Peroxisome proliferator-activated
receptor α (PPARα,ab8934), Peroxisome proliferator-
activated receptor γ (PPARγ, SC7273), fatty acid binding
protein (FABP, ab174673), Apolipoprotein A-I(ApoA-
I,ab334707), Carnitine palmitoyltransferase 1A(CPT-1A,
ab128568), 3-hydroxy-3methyl-glutaryl-CoA reductase
(HMGCR(H-300), SC-33827,SANTA), P450(Anti-Cyto-
chrome P450 Reductase antibody, ab13513), peroxisome
proliferator activated receptor coactivator 1 alpha(PGC-
1α, ab54481), AKT1/2(ab6067), Phosphatidylinositol 3-
kinase(PI3K, ab151549) and extracellular signal-regulated
kinase(ERK1/2, ab54230). The primary antibody was firstly
incubated, and then the secondary antibodies (Santa Cruz
Biotechnology Inc., CA, U.S.A.) was added. After being ex-
posed to chemiluminescence developing agents, the protein
levels and GAPDH in each sample were evaluated. The gel
was scanned and the band densities were quantified. The
band densities of proteins were normalized by the GAPDH
band densities to determine their concentrations.
Statistical analysis
Data were presented as mean ± standard deviation.
Differences among groups were analyzed by one-way
analysis of variance (ANOVA) test. P values of smaller
than 0.05 were considered as statistically significant. All
statistical analyses were carried out by SPSS 17.0 software.
Results
Effects of DQP and DS on cardiac functions
Twenty eight days after surgery, ultrasonography was
performed to evaluate heart functions in different groups
of animals. LVEDd and LVEDs increased significantly in
the model group compared with those in the sham
Table 1 Nucleotide sequences of primers used in real-time PCR
Gene(accession no.) Primers Nucleotiede sequences5′-3′ Size(bp) Temp(°C)
LPL Forward CGCTCCATCCATCTCTTC 18 57.3
Reverse GGCTCTGACCTTGTTGAT 18 55
ABCA1 Forward GTGGTGTTCTTCCTCGTTA 19 55.4
Reverse CTTCCGCTTCCTTCTGTAG 19 57.6
CD36 Forward GGCCCTTACACATACAGAGT 20 55.8
Reverse CCACAGCCAGATTGAGAA 18 55
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group, indicating that hypertrophy had developed as a
result of ischemia in rats that underwent ligation sur-
gery. EF and FS were reduced by 39.91% (P < 0.05) and
44.6% (P < 0.05) in the model group compared with
those in the sham group, suggesting that cardiac func-
tions were severely impaired in the model rats. After
treatments with DQP, LVEDd and LVEDs were down-
regulated by 32.14% (P < 0.05) and 28% (P > 0.05), and
EF and FS were up-regulated by 15.03% (P < 0.05) and
63.40% (P < 0.05) in the DQP treatment group compared
with those in the model group. In DS treatment group,
EF and FS value were also improved compared with
those in the model group (Table 2). These data indicated
that DQP and DS could exert anti-hypertrophy and car-
dioprotective effects in ischemic heart.
Effects of DQP and DS on proteins associated with lipid
metabolism
Expressions of lipoproteins and proteins involved in lipid
metabolism were detected. ApoA-I, the major protein
component of HDL, can promote cholesterol reversal
transport by activating lecithin cholesterolacyltransferase
(LCAT) [17]. Level of ApoA-I in model group (0.77 ±
0.07) was reduced compared as that in the sham group
(1.00 ± 0.00) (P < 0.01). DQP and DS could increase
plasma levels of ApoA-1 (1.41 ± 0.11, 1.40 ± 0.11) (P < 0.01),
promoting transportation of lipids from tissues to the liver
for excretion (Fig. 1). Lipoprotein lipase (LPL) hydrolyzes
triglycerides in lipoproteins and promotes cellular uptake
of chylomicron remnants and cholesterol-rich lipoproteins
[18]. Transcription level of LPL in model group was re-
duced. After treatment with DQP and DS, LPL was up-
regulated significantly (Table 3). ATP-binding cassette
transporter (ABCA1), which is involved in cholesterol ef-
flux pumping and formation of HDL, was down-regulated
in model group compared with that in the sham group.
Expression of ABCA1 was up-regulated after treatment
with DS (Table 3).
Membrane molecules that are involved in lipid uptake
into myocardial cells and mitochondria for oxidation were
also detected. Key membrane proteins includes: CD36,
fatty acids binding protein 4(FABP4), and carnitine palmi-
toyl transferase 1A (CPT-1A). Expression of CD36 and
CPT-1A were significantly reduced in model group com-
pared with those in the sham group (P < 0.05). Expression
of FABP4 was also reduced in ischemic heart tissue, but
the reduction showed no statistical significance. After
treatment with DQP and DS for 28 days, expressions of
both FABP4 and CPT-1A were up-regulated significantly,
indicating that expressions of these molecules were acti-
vated and uptake of lipids into cardiac cell were improved
(Table 3 and Fig. 1). No statistical differences were ob-
served between effects of the DQP and DS.
Effects of DQP and DS on cholesterol synthesis and
metabolism
HMGCR is the rate-limiting enzyme in cholesterol syn-
thesis. Inhibiting HMGCR is an effective way in redu-
cing plasma level of cholesterol and HMGCR is the
target of statins [19]. In model group, HMGCR was up-
regulated compared with sham group (P < 0.05). After
treatment with DQP, HMGCR was significantly reduced
(P < 0.001). However, DS had no effect on expression of
HGMCR (P > 0.05) (Fig. 2).
Cytochrome P450 is involved in lipid modification and
cholesterol metabolism [20]. P450 level was increased in
model group compared with that in the sham group
(P < 0.01). After treatment with DQP and DS, P450
level was reduced significantly compared with that in
the model group (P < 0.01), indicating that DQP and
DS could affect lipid metabolism by regulating levels
of P450 enzymes (Fig. 2). The inhibition effects of
DQP and DS on P450 were similar.
Effects of DQP and DS on PPARs, RXRA and PGC-1α
PPARs are the master transcription factors in energy
metabolism [21, 22]. PPARα can bind with retinoic acid
receptor alfa (RXRA) to form heterodimer, promoting
transcription of fatty acid oxidation genes [23]. PGC-1α
is a transcriptional coactivator that regulates the genes
involved in energy metabolism [24, 25]. Expression
changes of these factors in different groups of rats were
detected. Western blot showed that PPARα, PPARγ,
RXRA and PGC-1α were down-regulated by 24.25%
(P > 0.05), 64.8% (P < 0.01), 42.09% (P < 0.05) and 61.97%
(P < 0.05) in model group compared with those in sham-
operated group, respectively. After treatment with DQP,
expressions of PPARα, PPARγ, RXRA and PGC-1α were
up-regulated by 141.31% (P < 0.001), 352.54% (P < 0.001),
123.71% (P < 0.001) and 103.41% (P < 0.05) in DQP
Table 2 Indicators of heart functions tested by Echocardiography in different groups of rats
Sham Model Positive drug DQP DS
LVEDd(cm) 0.64 ± 0.05* 1.12 ± 0.21 1.08 ± 1.68 0.76 ± 0.064* 0.83 ± 0.18
LVEDs(cm) 0.41 ± 0.02** 0.75 ± 0.05 0.48 ± 0.08* 0.54 ± 0.080 0.64 ± 0.11
EF 0.68 ± 0.06** 0.41 ± 0.03 0.46 ± 0.06 0.47 ± 0.03* 0.53 ± 0.01*
FS(%) 37.39 ± 5.19* 20.71 ± 1.68 21.70 ± 5.78 33.84 ± 6.90* 36.43 ± 8.76*
*v.s. model group, P < 0.05, **v.s. model group, P < 0.01
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group compared with those in model group, respectively.
DS could also up-regulate expressions of these factors.
PPARα, PPARγ, RXRA and PGC-1α were increased by
69.66% (P < 0.05), 640.89% (P < 0.001), 140.08% (P < 0.001)
and 289.80% (P < 0.001) in DS group compared with those
in model group, respectively (Fig. 3). The effects of DS on
PPARγ, RXRA and PGC-1α were more remarkable com-
pared with those of DQP, whereas DQP showed better
effect in increasing expression of PPARα than DS.
Effects of DQP and DS on PI3K/AKT and ERK1/2
PI3K/AKT and mitogen-activated protein kinase (MAPK)/
ERK1/2 are important cardio-protective survival pathways
[26]. Expressions of PI3K and AKT1/2 were down-
regulated by 63.41% (P < 0.05) and 60.23% (P < 0.001) in
model rats compared with those in sham-operated rats,
indicating that PI3K/ATK pathway was inhibited in
ischemic heart tissue. Expression of ERK1/2 was also sup-
pressed in model group compared to sham-operated
group (Fig. 4). Treatments with DQP or DS could increase
expressions of PI3K/AKT and ERK1/2, re-activating the
signaling pathways. Compared with model group, expres-
sions of PI3K, AKT1/2 and ERK1/2 in DQP group were
up-regulated by 89.62% (P > 0.05), 96.39% (P < 0.001) and
138.67% (P < 0.001), respectively. In DS group, expres-
sions of PI3K, AKT1/2 and ERK1/2 were up-regulated
by 521.05% (P < 0.001), 189.82% (P < 0.001) and 213.96%
(P < 0.001), respectively. The effects of DS on PI3K/Akt
and ERK1/2 were more remarkable than DQP, sug-
gesting that the cardio-protective effects of DS might
be mediated by activating PI3K/Akt and ERK path-
ways (Fig. 4).
Discussion
In this study, we successfully induced rat model of ische-
mic coronary heart disease. Based on this model, we in-
vestigated the pharmacological mechanisms of DQP and
its major components DS in the treatment of CHD. In
the drug dosages we applied, cardiac functions were sig-
nificantly improved as evidenced by reduced LVED and
increased FS, suggesting that the current dosages were
effective. Our major findings are as follows: 1) Both
DQP and DS could exert cardioprotective effects under
Fig. 1 Expressions of ApoA-1, FABP4 and CPT-1A in five groups of rats. Western blot showed that compared with model group, expressions of
these three molecules were significantly up-regulated towards normal levels in DQP and DS groups. a Semi-quantitative expressions of ApoA-1 in
different groups. b Semi-quantitative expressions of FABP4 in different groups. c Semi-quantitative expressions ofCTP-1A in different groups. n = 6,
* v.s. model group, P < 0.05; ** v.s. model group, P < 0.01
Table 3 mRNA expressions of LPL, CD36 and ABCA1 in each
groups
Sham Model Positive DQP DS
LPL 3.56 ± 2.75* 0.15 ± 0.07 1.75 ± 0.76** 1.05 ± 0.60* 1.45 ± 0.81*
ABCA1 0.84 ± 0.60* 0.27 ± 0.21 1.36 ± 0.56* 1.30 ± 0.95 1.51 ± 0.67**
CD36 1.27 ± 0.97* 0.76 ± 0.46 0.84 ± 1.03 0.77 ± 0.30 0.94 ± 0.57
*v.s. model group, *P < 0.05; **P < 0.01
Wang et al. BMC Complementary and Alternative Medicine  (2016) 16:514 Page 5 of 10
Fig. 2 Expressions of HMGCR and P450 in different groups. a Semi-quantitative expressions of HMGCR in different groups. b Semi-quantitative
expressions of P450 in different groups. n = 6,* v.s. model group, P < 0.05; ** v.s. model group, P < 0.01; ## v.s. DQP group, P < 0.01
Fig. 3 Expressions transcription regulators in five groups of rats. a Semi-quantitative expressions of PPAR-α in different groups. b Semi-quantitative
expressions of PPAR-γ in different groups. c Semi-quantitative expressions of RXRA in different groups. d Semi-quantitative expressions of PGC-1α in
different groups. n = 6, * v.s. model group, P < 0.05; ** v.s. model group, P < 0.01, ## v.s. DQP group, P < 0.01
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ischemic conditions. Heart functions were reserved in
DQP and DS groups. 2) DQP and DS improved fatty
acid oxidation in ischemic heart by up-regulating mole-
cules involved in fatty acids transportation and uptake.
3) Both DQP and DS could up-regulate expressions of
PPARα, PPARγ and RXRA. DQP was a better agonist of
PPARα than DS, whereas the effects of DS on PPARγ,
RXRA and PGC-1α were greater than those of DQP. 4)
Expressions of PI3K/Akt and ERK1/2 were activated by
DQP and DS. These results suggest that DQP and DS
improve cardiac energy metabolism by up-regulating
transcription factors such as PPARα, PPARγ and PGC-
1α, thus providing cardioprotective effects under
ischemic conditions. The effects of DQP and DS are
comparable, indicating that DS are the major effective
components in regulating energy metabolism.
Our previous studies illustrated that DanQi pill could
regulate fatty acids metabolism in ischemic heart tissue.
Not only can dyslipidemia cause coronary heart disease
but coronary artery ligation can also induce dyslipidemia
[9]. In this study, we re-confirmed that DQP could regu-
late components of apolipoprotein and key molecules in-
volved in lipid transportation and uptake in ischemic
heart model. Epidemiological studies showed that levels
of HDL are inversely correlated with risk of cardiovascu-
lar events, whereas LDL levels are directly related to rate
of these events [27, 28]. HDL protects against cardiovas-
cular disease by regulating cholesterol efflux from tissues
and modulating inflammation [29]. ApoA-1, the major
protein component of HDL, is largely responsible for re-
verse cholesterol transport through the macrophage
ATP-binding cassette transporter ABCA1 [30, 31]. Our
study showed that expressions of ApoA-1 and ABCA1
were down-regulated in model group and treatments
with DQP and DS up-regulated their expressions.
Several key molecules are involved in fatty acids trans-
port and uptake by myocardiocyte. Fatty acid translo-
case/cluster of differentiation protein (CD36), a class of
membrane protein, facilitates transport of long chain
fatty acid into myocardiocyte [31, 32]. Plasma fatty acids
are translocated into cardiac myocytes by FABP4 on the
membrane and further transported into mitochondria by
CPT-I. CPT-1A is one of the most abundant subtypes of
CPT-I, which is the key enzyme in fatty acid oxidation
process [33]. Fatty acid transport protein 4 (FATP4) is
also involved in long- and very long-chain fatty acid up-
take and facilitate acyl-CoA synthesis [34, 35]. These key
molecules were down-regulated in model rats and treat-
ments with DQP and DS significantly improved their ex-
pressions, suggesting that the lipid transport and uptake
pathways could be regulated by DQP and DS. Further-
more, DQP could inhibit synthesis of cholesterol by
Fig. 4 Expressions of PI3K, AKT1/2 and ERK1/2 in different groups. a Semi-quantitative expressions of PI3K in different groups. b Semi-quantitative
expressions of AKT1/2 in different groups. c Semi-quantitative expressions of ERK1/2 in different groups. * v.s. model group, P < 0.05; ** v.s. model
group, P < 0.01; ## v.s. DQP group, P < 0.05; ## vs DQP group, P < 0.01
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reducing expression of HMGCR. DS didn’t seem to
have effect on HMGCR, indicating that the inhibitory
effect on cholesterol synthesis may be mediated by
components other than Salvianolic acids or Panax
notoginseng saponins.
Fatty acids oxidation provides the majority of energies
needed for cardiac contraction and this process is tightly
regulated by transcription factors. We further investi-
gated the effect of DQP and DS on transcriptional regu-
lation of energy metabolism. The PPAR family is a class
of transcription factors that regulate cardiac fuel metab-
olism at the gene expression level. The three PPAR fam-
ily members (α, β/δ and γ) are uniquely suited to serve
as transducers of developmental, physiological, and diet-
ary cues that influence cardiac fatty acid and glucose
metabolism [22]. The principal transcriptional regulator
of fatty acid oxidation (FAO) enzyme genes is PPARα
[20]. PPARγ is a primary target for thiazolidinedione-
structured insulin sensitizers like pioglitazone and rosi-
glitazone employed for the treatment of type 2 diabetes
mellitus [36]. PGC-1α is transcriptional coactivator of
the PPARs and is a key player in the control of myocar-
dial metabolism. In cardiac myocytes, activation of PGC-
1α drives a strong induction of PPARα target genes
encoding FAO enzymes [14]. PGC-1α also coactivates
other transcription factors, including estrogen-related
receptors and the nuclear respiratory factor 1, to stimu-
late mitochondrial biogenesis and enhance expression of
components of the electron transport chain [37]. In is-
chemic heart disease, the expression and/or DNA bind-
ing activity of the PPARα-RXR complex is markedly
diminished by hypoxia, which results in decreased ex-
pression of genes encoding enzymes involved in mito-
chondrial FAO and oxidative phosphorylation pathways
[38, 39]. The role of PPARs in ischemia is controversial.
Some studies found that chronic activation of PPARα is
detrimental to cardiac recovery after ischemia and
PPARγ activator was associated with increased mortality
post-myocardial infarction in rats [40–42]. In our study,
we found that expressions of PPARα, PPARγ, RXRA and
PGC-1α were all down-regulated in ischemic model
group. After treatments with DQP or DS for 28 days,
the expressions of these transcriptional factors were up-
regulated compared with those in the model group.
DQP showed better effect on PPARα, whereas DS
seemed to be more effective in up-regulating PPARγ and
PGC-1α. The different effects exerted by DQP and DS
may be due to complex interactions of different compo-
nents in DQP compound [43]. These results demonstrated
that up-regulating transcription factors targeting energy
metabolism are cardio-protective under ischemic condi-
tions. Components of DS may serve as ligand activators of
PPARs. Besides DS, other compounds in DQP may also
activate expressions of PPARα, as DQP improved PPARα
expression in a more remarkable way. The exact mechan-
ism by which DQP up-regulates PPARs warrants further
studies. The active compounds in DQP, other than DS,
also need further investigation.
The potential effects of DQP and DS on signaling path-
way were also studied. It is widely accepted that phos-
phatidylinositol 3-kinase (PI3K) signaling to Akt is an
important regulator of many cellular processes including
proliferation, apoptosis and nitric oxide synthesis [44].
PI3K also increases cardiac fatty acid oxidative capacity
[45]. Activation of PI3K/Akt pathway has been shown to
play a key role in myocardial preconditioning [46]. PI3K
signaling cascade reduces myocardial damage after ische-
mia by recruiting multiple endogenous cardioprotective
pathways. ERK1/2 belongs to the MAPKs family and acti-
vation of ERK1/2 in cardiac myocytes serves as a defense
mechanism against ischemic stress stimuli [47]. In this
study, we found that expressions of PI3K, Akt1/2 and
ERK1/2 were all reduced in model rats, and administra-
tions of DQP and DS increased the expressions of these
molecules, indicating that activation of PI3K/Akt and
ERK1/2 is protective under ischemic conditions and DQP
could activate the signaling pathway.
Conclusions
DS are the major effective components of DQP in im-
proving energy metabolism in ischemic heart disease
model. The effects may be mediated by regulating tran-
scriptional factors such as PPARs, RXRA and PGC-1α.
Further study into the pharmacological mechanisms of
Salvianolic acids and Panax notoginseng will provide
insight into the discovery of new drugs targeting PPARs
and PGC-1α and new strategies in the management of
cardiovascular diseases.
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